Integrated Quantitative Investments LLC Buys Shares of 4,900 ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Integrated Quantitative Investments LLC purchased a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,900 shares of the specialty pharmaceutical company’s stock, valued at approximately $271,000.

Several other institutional investors and hedge funds also recently made changes to their positions in ANIP. Geode Capital Management LLC grew its holdings in ANI Pharmaceuticals by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 428,999 shares of the specialty pharmaceutical company’s stock worth $23,720,000 after acquiring an additional 3,774 shares during the last quarter. Loomis Sayles & Co. L P grew its stake in shares of ANI Pharmaceuticals by 11.2% in the fourth quarter. Loomis Sayles & Co. L P now owns 194,185 shares of the specialty pharmaceutical company’s stock worth $10,735,000 after purchasing an additional 19,568 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $166,000. Sei Investments Co. increased its holdings in ANI Pharmaceuticals by 13.7% in the fourth quarter. Sei Investments Co. now owns 22,774 shares of the specialty pharmaceutical company’s stock valued at $1,259,000 after purchasing an additional 2,752 shares during the period. Finally, Teacher Retirement System of Texas raised its position in ANI Pharmaceuticals by 18.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,999 shares of the specialty pharmaceutical company’s stock worth $276,000 after purchasing an additional 793 shares during the last quarter. Institutional investors and hedge funds own 76.05% of the company’s stock.

Insider Buying and Selling

In related news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company’s stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares of the company’s stock, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,200 shares of company stock valued at $191,776. 12.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

ANIP has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Jefferies Financial Group assumed coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They set a “buy” rating and a $80.00 price target for the company. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, March 14th. Finally, Leerink Partners initiated coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.75.

ANI Pharmaceuticals Stock Down 1.1 %

Shares of NASDAQ ANIP opened at $67.52 on Friday. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The company’s fifty day simple moving average is $61.45 and its 200 day simple moving average is $58.78. The firm has a market cap of $1.47 billion, a PE ratio of -122.76 and a beta of 0.63. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $70.00.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.